In This Article:
SUNNYVALE, Calif., April 25, 2025 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF) is pleased to announce the voting results from its annual general and special meeting of shareholders held on April 25, 2025 (the "Meeting"). A total of 59,214,893 common shares, representing approximately 40.88% of the Company's issued and outstanding shares were represented at the meeting.
The shareholders approved the setting of the number of directors of Willow at 5 directors, and the following nominees were elected as directors of Willow for the ensuing year with the specific voting results being as follows:
| | Votes For | Votes Withheld | ||
| Director | # | % | # | % |
| Dr. Chris Savile | 46,902,346 | 88.3 % | 6,234,676 | 11.7 % |
| Dr. Jim Lalonde | 46,965,380 | 88.4 % | 6,171,642 | 11.6 % |
| Donald Archibald | 44,900,287 | 84.5 % | 8,236,735 | 15.5 % |
| Raffi Asadorian | 46,963,057 | 88.4 % | 6,173,965 | 11.6 % |
| Al Foreman | 46,900,723 | 88.3 % | 6,236,299 | 11.7 % |
In addition, shareholders approved the below matters. The resolutions approving the below matters may be viewed in full in the Company's management information circular dated March 26, 2025 (the "Information Circular").
| | Votes For | |
| Director | # | % |
| Appointment of KPMG LLP as the Company's auditor for the ensuring year | 51,882,364 | 87.6 % |
| The proposed sale of the shares of Epimeron USA, Inc., the Corporation's | 46,996,397 | 88.4 % |
| To authorize the Corporation's board of directors, at its sole discretion, to | 48,853,362 | 82.5 % |
For complete voting results on all matters approved at the Meeting, please see the Company's Report of Voting Results dated April 25, 2025, available on SEDAR+ at www.sedarplus.ca.
About Willow Biosciences Inc.
Willow develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Willow's FutureGrownTM biotechnology platform allows large-scale production with sustainability at its core. Willow's R&D team has a proven track record of developing and commercializing bio-based manufacturing processes and products to benefit our B2B partners and their customers.